Fernando Escalante

1.8k total citations
36 papers, 325 citations indexed

About

Fernando Escalante is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Fernando Escalante has authored 36 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 14 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Fernando Escalante's work include Multiple Myeloma Research and Treatments (22 papers), Peptidase Inhibition and Analysis (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Fernando Escalante is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Peptidase Inhibition and Analysis (8 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Fernando Escalante collaborates with scholars based in Spain, United States and Canada. Fernando Escalante's co-authors include Ramón García‐Sánz, María‐Victoria Mateos, Alfonso García de Coca, Norma C. Gutiérrez, Noemí Puig, Enrique M. Ocio, Jesús F. San Miguel, Abelardo Bárez, Verónica González‐Calle and María‐Belén Vídriales and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Fernando Escalante

32 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fernando Escalante Spain 10 236 171 120 84 41 36 325
Hannah Hunter United Kingdom 8 312 1.3× 202 1.2× 160 1.3× 85 1.0× 63 1.5× 21 397
Miriam Hobbs United States 7 139 0.6× 129 0.8× 80 0.7× 75 0.9× 15 0.4× 26 225
Philip R. Greipp United States 7 201 0.9× 163 1.0× 117 1.0× 85 1.0× 40 1.0× 8 324
Vittorio Del Fabro Italy 9 134 0.6× 100 0.6× 93 0.8× 74 0.9× 23 0.6× 32 263
Eugene Nikitin Russia 8 73 0.3× 134 0.8× 48 0.4× 118 1.4× 76 1.9× 62 301
Cesare Bergonzi Italy 9 229 1.0× 175 1.0× 124 1.0× 40 0.5× 19 0.5× 19 318
Yaozhong Zhao China 10 219 0.9× 152 0.9× 146 1.2× 57 0.7× 27 0.7× 20 314
Catia Bigazzi Italy 11 181 0.8× 85 0.5× 121 1.0× 184 2.2× 148 3.6× 16 368
Xiaoqi Qin China 9 172 0.7× 156 0.9× 118 1.0× 35 0.4× 20 0.5× 27 284
Donna Bucci United States 10 129 0.5× 101 0.6× 97 0.8× 60 0.7× 69 1.7× 18 319

Countries citing papers authored by Fernando Escalante

Since Specialization
Citations

This map shows the geographic impact of Fernando Escalante's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Escalante with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Escalante more than expected).

Fields of papers citing papers by Fernando Escalante

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Escalante. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Escalante. The network helps show where Fernando Escalante may publish in the future.

Co-authorship network of co-authors of Fernando Escalante

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Escalante. A scholar is included among the top collaborators of Fernando Escalante based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Escalante. Fernando Escalante is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Moreno, David F., Cristina Jiménez, Fernando Escalante, et al.. (2024). Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry. HemaSphere. 8(11). e70029–e70029. 2 indexed citations
2.
Rubia, Javier de la, Rafael Alonso, Elham Askari, et al.. (2023). Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain. Cancers. 15(11). 2964–2964. 9 indexed citations
3.
Hultcrantz, Malin, David Kleinman, Ravi Vij, et al.. (2023). Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update.. Journal of Clinical Oncology. 41(16_suppl). e20046–e20046. 1 indexed citations
4.
González‐Calle, Verónica, Fernando Escalante, José Antonio Queizán, et al.. (2023). Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. Cancers. 15(5). 1558–1558. 36 indexed citations
5.
González‐Calle, Verónica, Fernando Escalante, Irène Bueno, et al.. (2023). Multiple myeloma with t(11;14): impact of novel agents on outcome. Blood Cancer Journal. 13(1). 40–40. 8 indexed citations
6.
García‐Sánz, Ramón, María García‐Álvarez, Alejandro Medina, et al.. (2023). Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level. Disease Models & Mechanisms. 16(8). 2 indexed citations
7.
Rubia, Javier de la, Rafael Alonso, Alfonso García de Coca, et al.. (2022). Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort. Blood. 140(Supplement 1). 4315–4317. 4 indexed citations
8.
9.
Lecumberri, Ramón, Isabel Krsnik, Marta Sonia González, et al.. (2020). Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. Amyloid. 27(3). 163–167. 25 indexed citations
10.
Durie, Brian G.M., Hartmut Goldschmidt, María‐Victoria Mateos, et al.. (2019). Outcomes of patients with t(11;14) multiple myeloma: An International Myeloma Working Group (IMWG) multicenter study.. Journal of Clinical Oncology. 37(15_suppl). 8015–8015. 4 indexed citations
11.
Jiménez, Cristina, María García‐Álvarez, Miguel Alcoceba, et al.. (2018). Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. Annals of Hematology. 97(3). 475–484. 17 indexed citations
12.
Arriba, Felipe de, Miguel Ángel Álvarez-Avitia, Marta Sonia González, et al.. (2017). Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation. Seminars in Hematology. 55(4). 189–196. 7 indexed citations
13.
González‐Calle, Verónica, Jorge Labrador, Carmen Aguilera, et al.. (2017). Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica. 102(5). 922–931. 27 indexed citations
14.
González‐Calle, Verónica, Julio Dávila, Fernando Escalante, et al.. (2016). Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia. 30(10). 2026–2031. 14 indexed citations
15.
Misiewicz-Krzemińska, Irena, María Eugenia Sarasquete, Carolina Vicente‐Dueñas, et al.. (2015). Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. Clinical Cancer Research. 22(1). 207–217. 25 indexed citations
16.
González‐Calle, Verónica, Julio Dávila, Enrique M. Ocio, et al.. (2015). Immunoparesis Recovery as Predictor Marker of Progression After Autologous Stem Cell Transplantation in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 15. S51–S51. 1 indexed citations
17.
González‐Calle, Verónica, Ramón García‐Sánz, Enrique M. Ocio, et al.. (2014). Bence Jones Proteinuria in Smoldering Multiple Myeloma As Predictor Marker of Progression to Symptomatic Multiple Myeloma. Blood. 124(21). 3369–3369. 4 indexed citations
18.
Paiva, Bruno, María‐Belén Vídriales, Enrique Colado, et al.. (2014). Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 124(8). 1300–1303. 46 indexed citations
19.
González‐Porras, José Ramón, Fernando Escalante, Emilia Pardal, et al.. (2013). Safety and efficacy of splenectomy in over 65‐yrs‐old patients with immune thrombocytopenia. European Journal Of Haematology. 91(3). 236–241. 47 indexed citations
20.
Fernández‐Flores, Angel, et al.. (2011). The Differential Diagnosis Between Primary Cutaneous Large B-cell Lymphoma and Cutaneous Follicular Lymphoma: Prognostic and Therapeutic Implications. American Journal of Dermatopathology. 33(8). 819–826. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hannah Hunter Breakdown of academic impact, for papers by Miriam Hobbs Breakdown of academic impact, for papers by Philip R. Greipp Breakdown of academic impact, for papers by Vittorio Del Fabro Breakdown of academic impact, for papers by Eugene Nikitin Breakdown of academic impact, for papers by Cesare Bergonzi Breakdown of academic impact, for papers by Yaozhong Zhao Breakdown of academic impact, for papers by Catia Bigazzi Breakdown of academic impact, for papers by Xiaoqi Qin Breakdown of academic impact, for papers by Donna Bucci
Rankless by CCL
2026